Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03772028 · ClinicalTrials.gov registry record · Phase 3
Primary Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
A Phase 3 study of Ovarian Cancer, sponsored by The Netherlands Cancer Institute.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 538
- Enrollment target
- 20
- Study locations
NCT03772028: Recruiting Phase 3 study of Ovarian Cancer, sponsored by The Netherlands Cancer Institute.
NCT03772028 is a Phase 3 study of Ovarian Cancer that is actively recruiting participants, run by The Netherlands Cancer Institute. The registered enrollment target is 538 participants, below the 727-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (26% lower). The trial reports 20 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03772028, a Phase 3 study of Ovarian Cancer, is actively recruiting participants, sponsored by The Netherlands Cancer Institute.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 538 participants
- Enrollment target
- 20
- Study locations
Study Summary
stage III epithelial ovarian cancer randomizing between primary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy
Conditions Studied
Interventions
- DRUG cisplatin
Study Locations (20)
Other
- Rigshospitalet Copenhagen - Copenhagen
- CHU de Besancon - Besançon
- Institut Bergonié - Bordeaux
- o Institut Bergonié, Bordeaux - Bordeaux
- CHU Lille - Lille
- Centre Leon Berard, Lyon - Lyon
- CHU Lyon - Lyon
- Institut du Cancer Montpellier - Montpellier
- Institut de Cancerologie de l'Ouest, ICO Nantes) - Nantes
- Institut Curie Paris - Paris
- CHRU Strasbourg - Strasbourg
- Oncopole, Institute Universitaire du Cancer de Toulouse (IUCT Toulouse) - Toulouse
- Mater Misericordiae University Hospital, Dublin - Dublin
- Policlinico Sant'Orsola, Bologna - Bologna
- Fondazione Policlinico A Gemelli IRCCS - Roma
- Amsterdam UMC - Amsterdam
- Catharina Hospital - Eindhoven
California
- City of Hope - Duarte
New York
- MSKCC New York - New York
North Holland
- Antoni van leeuwenhoek - Amsterdam
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 538 participants |
| Start Date | 2020-01-01 |
| Est. Completion | 2026-04-01 |
| Phase | Phase 3 |
What NCT03772028 shows while recruiting
NCT03772028 is an interventional study that assigns participants to a tested intervention. The registered 538 participants enrollment target is mid-sized for trials with a published cap, below the 727-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (26% lower).
The record links to 1 condition, with Ovarian Cancer appearing as the primary indexed condition, and to 1 intervention - of which cisplatin is the first listed.
NCT03772028 names 20 study sites across 4 states, led by Other, California, New York.
Frequently Asked Questions
What is clinical trial NCT03772028 about?
NCT03772028 is a clinical study titled "Primary Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy (HIPEC)". stage III epithelial ovarian cancer randomizing between primary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy
What is the current status of trial NCT03772028?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 538 participants. The study started on 2020-01-01. Estimated completion is 2026-04-01.
What conditions does trial NCT03772028 study?
This clinical trial studies the following conditions: Ovarian Cancer.
What interventions are being tested in trial NCT03772028?
The interventions under investigation include: cisplatin (DRUG).
Who is sponsoring clinical trial NCT03772028?
This trial is sponsored by The Netherlands Cancer Institute, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03772028 being conducted?
This trial has 20 study locations across California, New York, North Holland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03772028's enrollment target sits among peer trials
538 44th of 322 higher than 279 of 322 other Ovarian Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Ovarian Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Gleolan for Visualization of Newly Diagnosed or Recurrent Ovarian Cancer (OVA-302)
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
RECRUITING · Phase 3
-
Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer
RECRUITING · Phase 3
-
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
RECRUITING · Phase 3
-
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
RECRUITING · Phase 3
-
Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06538038 · 538 participants
Prospective Non-Interventional Study Comparing Osimertinib +/- Chemotherapy for EGFR-Mutated NSCLC Patients
- NCT05880004 · 537 participants · NA
Developing a Support Application for Food Pantries (SAFPAS) to Improve Client Access to Healthy Foods & Enhance Emergency Preparedness
- NCT04557462 · 540 participants · Phase 3
A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy
- NCT04956640 · 540 participants · Phase 1
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI